Curtin N - Search Results

1

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H. Plummer R, et al. Among authors: curtin n. Clin Cancer Res. 2008 Dec 1;14(23):7917-23. doi: 10.1158/1078-0432.CCR-08-1223. Clin Cancer Res. 2008. PMID: 19047122 Free PMC article. Clinical Trial.

2

Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.

Curtin NJ, Harris AL, Aherne GW. Curtin NJ, et al. Cancer Res. 1991 May 1;51(9):2346-52. Cancer Res. 1991. PMID: 2015598

3

Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole.

Curtin NJ, Newell DR, Harris AL. Curtin NJ, et al. Biochem Pharmacol. 1989 Oct 1;38(19):3281-8. doi: 10.1016/0006-2952(89)90626-6. Biochem Pharmacol. 1989. PMID: 2818627

4

Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.

Curtin NJ, Harris AL, James OF, Bassendine MF. Curtin NJ, et al. Br J Cancer. 1986 Mar;53(3):361-8. doi: 10.1038/bjc.1986.60. Br J Cancer. 1986. PMID: 3008799 Free PMC article.

5

Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.

Curtin NJ, Harris AL. Curtin NJ, et al. Biochem Pharmacol. 1988 Jun 1;37(11):2113-20. doi: 10.1016/0006-2952(88)90568-0. Biochem Pharmacol. 1988. PMID: 3377815

6

Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.

Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, Durkacz BW. Boulton S, et al. Among authors: curtin nj. Br J Cancer. 1995 Oct;72(4):849-56. doi: 10.1038/bjc.1995.423. Br J Cancer. 1995. PMID: 7547230 Free PMC article.

7

Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP).

Griffin RJ, Pemberton LC, Rhodes D, Bleasdale C, Bowman K, Calvert AH, Curtin NJ, Durkacz BW, Newell DR, Porteous JK, et al. Griffin RJ, et al. Among authors: curtin nj. Anticancer Drug Des. 1995 Sep;10(6):507-14. Anticancer Drug Des. 1995. PMID: 7575991 No abstract available.

8

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. Griffin RJ, et al. Among authors: curtin nj. Biochimie. 1995;77(6):408-22. doi: 10.1016/0300-9084(96)88154-5. Biochimie. 1995. PMID: 7578423 Review.

9

Probing the active site and mechanism of action of O6-methylguanine-DNA methyltransferase with substrate analogues (O6-substituted guanines).

Arris CE, Bleasdale C, Calvert AH, Curtin NJ, Dalby C, Golding BT, Griffin RJ, Lunn JM, Major GN, Newell DR. Arris CE, et al. Among authors: curtin nj. Anticancer Drug Des. 1994 Oct;9(5):401-8. Anticancer Drug Des. 1994. PMID: 7945724 No abstract available.

10

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Bowman KJ, et al. Among authors: curtin nj. Br J Cancer. 1998 Nov;78(10):1269-77. doi: 10.1038/bjc.1998.670. Br J Cancer. 1998. PMID: 9823965 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

293 results

Search Page

Filters